It is worthy to underline that double carbapenem therapy may offer similar clinical outcomes as ATM + CAZ-AVI for patients with infection caused by K. pneumoniae resistant to all available β-lactam/β-lactamase inhibitors [135]. Here, ATM is linked to infection.